Keyword Connections

vaccinia virus

Journals

3

1 Nano letters

2 viral immunology

3 jco global oncology

Research Groups

0

No Research Group Connected

Bibliographies

15

1 Administration with Vaccinia Virus Encoding Canine Parvovirus 2 Elicits Systemic Immune Responses in Mice and Dogs.

2 Opportunistic Screening of Oral Potentially Malignant Disorders: A Public Health Need for India.

3 Synthesis and single-particle surface-enhanced Raman scattering study of plasmonic tripod nanoframes with Y-shaped hot-zone.

4 infecção em humanos por varíola bovina na microrregião de itajubá, estado de minas gerais: relato de caso human infection by the cowpox virus in the microregion of itajubá, state of minas gerais: case report

5 serro 2 virus highlights the fundamental genomic and biological features of a natural vaccinia virus infecting humans

6 crispr-cas9 as a powerful tool for efficient creation of oncolytic viruses

7 Genome sequence of Vaccinia virus strain Lister- Butantan, a Lister vaccine variant used during a smallpox eradication campaign in Brazil

8 Passive transfer of respiratory syncytial virus (RSV) antiserum suppresses the immune response to the RSV fusion (F) and large (G) glycoproteins expressed by recombinant vaccinia viruses.

9 Passive transfer of respiratory syncytial virus (RSV) antiserum suppresses the immune response to the RSV fusion (F) and large (G) glycoproteins expressed by recombinant vaccinia viruses

10 Resistance to respiratory syncytial virus (RSV) challenge induced by infection with a vaccinia virus recombinant expressing the RSV M2 protein (Vac-M2) is mediated by CD8+ T cells, while that induced by Vac-F or Vac-G recombinants is mediated by antibodies.

11 Resistance to respiratory syncytial virus (RSV) challenge induced by infection with a vaccinia virus recombinant expressing the RSV M2 protein (Vac-M2) is mediated by CD8+ T cells, while that induced by Vac-F or Vac-G recombinants is mediated by antibodies

12 Heterotypic immunity against vaccinia virus in an HLA-B*07:02 transgenic mousepox infection model

13 Human and murine cytotoxic T cells specific to respiratory syncytial virus recognize the viral nucleoprotein (N), but not the major glycoprotein (G), expressed by vaccinia virus recombinants

14 Heterotypic immunity against vaccinia virus in an HLA-B*07:02 transgenic mousepox infection model

15 modified vaccinia virus ankara (mva) as production platform for vaccines against influenza and other viral respiratory diseases